There are 30,000 Americans living with Amyotrophic Lateral Sclerosis (ALS), a 100 percent fatal diagnosis that usually kills people in two to five years. Despite this currently grim outlook for patients, the Food and Drug Administration (FDA) has refused to exercise regulatory flexibility that would lead to faster approval and availability for ALS treatments.
We Cannot Wait: FDA Needs to Act on ALS
Comment
Show comments
Hide Comments
